These results suggest that lactylation of APOC2 at K70 plays a major role in mediating the oncogenic effect of FFA in NSCLC, and that anti‐APOC2K70‐lac Ab is an effective enhancer in tumor immunotherapy. This evidence concerns the gene APOC2 and non-small cell lung carcinoma.